Aclarion, Inc. ACON
leverages Magnetic Resonance Spectroscopy ("MRS"), and proprietary biomarkers to optimize clinical treatments. Aclarion's
technology addresses the $134.5B U.S. low back and neck pain market, which according to a 2020 JAMA (Journal of the American Medical Association)
article is now the most costly healthcare condition in the United States. The Company is currently utilizing Artificial Intelligence ("AI")
to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. The use of AI in this application is
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $75.7K | $45.7K | $75.4K | $60.4K | $60.3K | — |
| Cost of revenue | $68.9K | $84.7K | $75.7K | $65.3K | $69.2K | — |
| Gross profit | $6.8K | -$38.9K | -$324 | -$4.9K | -$8.9K | — |
| R&D | $1.0M | $888.8K | $873.3K | $1.1M | $787.9K | — |
| SG&A | $4.1M | $3.6M | $3.2M | $4.0M | $1.8M | — |
| Total operating expenses | $7.1M | $5.5M | $4.9M | $5.6M | $2.9M | — |
| Operating income | -$7.1M | -$5.5M | -$4.9M | -$5.6M | -$3.0M | — |
| Interest expense | — | $64.1K | $110.5K | $1.5M | $474.9K | — |
| Pre-tax income | -$7.2M | -$7.0M | -$4.9M | -$7.1M | -$5.0M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$7.2M | -$7.0M | -$4.9M | -$7.1M | -$5.0M | — |
| EPS, basic | -13.61 | -7,478.90 | -79,782.00 | -19.61 | -6.58 | — |
| EPS, diluted | -13.61 | -7,478.90 | -79,782.00 | -19.61 | -6.58 | — |
| Shares, diluted (wtd. avg.) | $532.0K | $943 | $62 | $381.6K | $905.7K | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $12.0M | $453.7K | $1.0M | $1.5M | $452.5K | $15.0K |
| Receivables | $29.7K | $18.3K | $13.3K | $18.6K | $6.3K | — |
| Total current assets | $12.4M | $824.3K | $1.3M | $1.7M | $732.2K | — |
| Property, plant and equipment | $24.2K | $5.5K | $1.8K | $3.3K | $12.6K | — |
| Other intangibles | $1.3M | $1.3M | $1.2M | $1.2M | $1.1M | — |
| Total assets | $13.7M | $2.1M | $2.5M | $2.9M | $1.9M | — |
| Accounts payable | $333.0K | $531.6K | $760.5K | $462.2K | $1.1M | — |
| Total current liabilities | $837.3K | $1.2M | $3.2M | $688.7K | $7.6M | — |
| Total liabilities | $837.3K | $1.2M | — | — | — | — |
| Retained earnings | -$58.5M | -$51.3M | -$44.3M | -$39.4M | -$31.9M | — |
| Total equity | $12.8M | $970.1K | -$728.0K | $2.2M | -$12.8M | -$7.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.2M | -$5.3M | -$3.6M | -$4.9M | -$2.4M | — |
| Depreciation and amortisation | $227.4K | $193.1K | $162.7K | $4.5K | $13.0K | — |
| Stock-based compensation | $105.4K | $287.5K | $456.0K | $1.2M | $177.5K | — |
| Capital expenditure | $21.5K | $5.1K | $0 | — | — | — |
| Investing cash flow | -$203.9K | -$321.9K | -$119.5K | -$207.9K | -$102.0K | — |
| Financing cash flow | $18.9M | $5.0M | $3.3M | $6.2M | $2.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-001986.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $47.31B | — | 35.9% |
| LH | LABCORP HOLDINGS INC. | $26.51B | 31.3x | 7.2% |
| DGX | QUEST DIAGNOSTICS INC | $26.17B | 27.1x | 11.8% |
| GH | Guardant Health, Inc. | $21.66B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $7.08B | — | 97.0% |
| RDNT | RadNet, Inc. | $5.80B | — | 11.5% |
| CELC | Celcuity Inc. | $4.68B | — | — |
| BLLN | BillionToOne, Inc. | $4.61B | 709.9x | 100.0% |